The hon. Lady has raised a particular case about Heidi, her constituent, and obviously I am sorry to hear that Heidi is in these circumstances. On the question of the drugs and treatments that are available, obviously we have a robust independent process through the National Institute for Health and Care Excellence reviews to look at new medicines that are possible, and this is the case with Spinraza. I am pleased that Biogen has, as I understand it, submitted a revised submission for the NICE appraisal committee to consider and a meeting has been arranged for 6 March when those recommendations will be considered.